Circulating microRNAs: Biomarkers of disease

Wu, Yudong; Li, Qian; Zhang, Renshuai; Dai, Xiaoli; Chen, Wujun; Xing, Dongming

doi:10.1016/j.cca.2021.01.008

Cited by 111 publications

(67 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on their readily accessible and minimally invasive properties, ncRNAs, and in particular miRNAs and lncRNAs, have emerged as promising diagnostic and prognostic biomarkers in a wide range of diseases [ 68 , 69 , 70 ]. Furthermore, these molecules show optimal biological properties, such as high stability against degradation, a long biological half-life, and easy detection through available techniques in laboratories, such as qPCR [ 68 , 71 , 72 ].…”

Section: Discussionmentioning

confidence: 99%

Are Non-Coding RNAs Useful Biomarkers in Parathyroid Tumorigenesis?

Aurilia

Donati

Palmini

et al. 2021

IJMS

View full text Add to dashboard Cite

Tumors of the parathyroid glands are common endocrine diseases almost always characterized by parathyroid hormone hypersecretion that determines the clinical manifestations of primary hyperparathyroidism, such as fatigue, kidney problems, weakness, brittle bones, and other symptoms. Most parathyroid neoplasia are benign adenomas, although rare malignant forms have been described. They are heterogeneous in terms of clinical presentation and the associated signs and symptoms overlap with those of disease and aging. Furthermore, most patients with hypercalcemia are discovered during routine blood tests for other reasons. Surgical removal is considered the main therapeutic option to cure these endocrine tumors and, therefore, innovative therapeutic approaches are actively required. Recently, a growing number of studies have suggested that alterations to the epigenetic mechanisms could play a pivotal role in parathyroid tumorigenesis. Most of the attention has been focused on non-coding RNAs (ncRNAs) (i.e., miRNAs, lncRNAs, and circRNAs) whose expression profile has been found to be deregulated in parathyroid tumors. The aim of the present paper is to give an insight into the ncRNAs involved in parathyroid tumorigenesis, which could be used in the future either as innovative diagnostic biomarkers or as therapeutic targets for the treatment of this endocrine neoplasia.

show abstract

Section: Discussionmentioning

confidence: 99%

Are Non-Coding RNAs Useful Biomarkers in Parathyroid Tumorigenesis?

Aurilia

Donati

Palmini

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…ABCA1 is a key mediator of intracellular cholesterol efflux to apoA-I for the generation of high-density lipoprotein (HDL), which protects against atherosclerotic vascular diseases by transferring cholesterol from peripheral cells to the liver for biliary excretion, constituting the process of reverse cholesterol transport (RCT). [58][59][60] Previous studies by our laboratory and others have demonstrated that ABCA1 plays a critical role in preventing cholesterol accumulation in macrophages,…”

Section: Role Of Abca1 In Atherosclerosismentioning

confidence: 97%

New Horizons for the Roles and Association of APE1/Ref-1 and ABCA1 in Atherosclerosis

Chen¹,

Wang²,

Xing³

2021

JIR

Self Cite

View full text Add to dashboard Cite

Atherosclerosis is the leading cause of death worldwide. APE1/Ref-1 and ABCA1 play key roles in the progression of atherosclerosis. APE1/Ref-1 suppresses atherosclerosis via multiple mechanisms, including reducing the IL-6-, TNF-α-, and IL-1βmediated proinflammatory responses, suppressing ROS-mediated oxidant activity and Bax/ Bcl-2-mediated vascular calcification and apoptosis, and reducing LOX-1-mediated cholesterol uptake. However, APE1/Ref-1 also promotes atherosclerosis by increasing the activity of the NK-κB and S1PR1 pathways. APE1/Ref-1 localizes to the nucleus, cytoplasm, and mitochondria and can be secreted from the cell. APE1/Ref-1 localization is dynamically regulated by the disease state and may be responsible for its proatherogenic and antiatherogenic effects. ABCA1 promotes cholesterol efflux and anti-inflammatory responses by binding to apoA-I and regulates apoptotic cell clearance and HSPC proliferation to protect against inflammatory responses. Interestingly, in addition to mediating these functions, ABCA1 promotes the secretion of acetylated APE1/Ref-1 (AcAPE1/Ref-1), a therapeutic target, which protects against atherosclerosis development. The APE1/Ref-1 inhibitor APX3330 is being evaluated in a phase II clinical trial. The LXR agonist LXR-623 (WAY-252623) is an agonist of ABCA1 and the first LXR-targeting compound to be evaluated in clinical trials. In this article, we review the roles of ABCA1 and APE1/Ref-1 in atherosclerosis and focus on new insights into the ABCA1-APE1/Ref-1 axis and its potential as a novel therapeutic target in atherosclerosis.

show abstract

“…A large amount of literature documents the wide involvement of miRNAs in cancer as key players in the development and progression of different malignancies (reviewed in reference [5]), as diagnostic/prognostic biomarkers (reviewed in reference [6]) and as potential therapeutic targets [7].…”

Section: Introductionmentioning

confidence: 99%

Epitranscriptomics: A New Layer of microRNA Regulation in Cancer

Paolis

Lorefice

Orecchini

et al. 2021

Cancers

View full text Add to dashboard Cite

MicroRNAs are pervasive regulators of gene expression at the post-transcriptional level in metazoan, playing key roles in several physiological and pathological processes. Accordingly, these small non-coding RNAs are also involved in cancer development and progression. Furthermore, miRNAs represent valuable diagnostic and prognostic biomarkers in malignancies. In the last twenty years, the role of RNA modifications in fine-tuning gene expressions at several levels has been unraveled. All RNA species may undergo post-transcriptional modifications, collectively referred to as epitranscriptomic modifications, which, in many instances, affect RNA molecule properties. miRNAs are not an exception, in this respect, and they have been shown to undergo several post-transcriptional modifications. In this review, we will summarize the recent findings concerning miRNA epitranscriptomic modifications, focusing on their potential role in cancer development and progression.

show abstract

Circulating microRNAs: Biomarkers of disease

Cited by 111 publications

References 149 publications

Are Non-Coding RNAs Useful Biomarkers in Parathyroid Tumorigenesis?

Are Non-Coding RNAs Useful Biomarkers in Parathyroid Tumorigenesis?

New Horizons for the Roles and Association of APE1/Ref-1 and ABCA1 in Atherosclerosis

Epitranscriptomics: A New Layer of microRNA Regulation in Cancer

Contact Info

Product

Resources

About